Outlook Therapeutics (OTLK) CFO Kenyon Receives Stock Option Award

What Happened
Lawrence A. Kenyon, Chief Financial Officer of Outlook Therapeutics (OTLK), received a grant of 210,078 derivative securities (stock options) on July 21, 2026. The Form 4 reports the acquisition at $0.00 per share (derivative award), meaning this was an option/award grant rather than a cash purchase or sale. The options vest and become exercisable in full on July 21, 2027, subject to Kenyon’s continued service.

Key Details

• Transaction date: 2026-07-21; Form filed: 2026-07-23 (timely filing).
• Instrument: 210,078 stock options awarded (reported at $0.00 per share).
• Vesting: Options vest and become exercisable in full on 2027-07-21, contingent on continued service (per footnote).
• Shares owned after transaction: not specified in the provided filing details.
• Footnote: Grant made under the Issuer’s 2024 Equity Incentive Plan and the standard stock option agreement.
• Filing timeliness: Report appears timely (filed two days after the transaction).

Context
This was a grant of options (a future/derivative interest), not an immediate cash transaction or sale. Such awards are commonly used for retention and incentive compensation; they do not indicate an immediate change in the insider’s market exposure until vested/exercised.